Literature DB >> 32773572

The potential of a ketogenic diet to minimize effects of the metabolic fault in glycogen storage disease V and VII.

Stacey L Reason1, Richard J Godfrey2.   

Abstract

PURPOSE OF REVIEW: To explore the potential of a low carbohydrate ketogenic diet (LCKD) to counter physical activity intolerance, pain and muscle damage for glycogen storage disease (GSD) V and VII, and highlight the realistic possibility that nutrition could be key. RECENT
FINDINGS: Carbohydrate (CHO) ingestion during physical activity in GSDV and a LCKD for GSDVII is common. For the latter, a long-term study demonstrated improvement in physiological markers while on a LCKD. This included improvement in aerobic power and activity tolerance. In GSDV, preliminary research on a LCKD suggest a diet of 75% fat, 15% protein, 10% CHO, is best for improved function and compliance. Ketones provide immediate fuel for acute physical activity, and have an epigenetic role, improving ketone and lipid use. Evidence from elite athletes found a LCKD can increase fat oxidation and is optimal at 70% VO2max. This suggests the need to also improve conditioning via exercise to maximize the benefit of a LCKD.
SUMMARY: A high CHO diet in GSDV and VII comes with a restricted physical activity capacity alongside significant pain, muscle damage and risk of renal failure. Mounting evidence suggests a LCKD is efficacious for both disorders providing an immediate fuel source which may negate the need for a 'warm-up' prior to every activity and restore 'normal' function.

Entities:  

Year:  2020        PMID: 32773572     DOI: 10.1097/MED.0000000000000567

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  1 in total

1.  A new phenotype of aldolase a deficiency in a 14 year-old boy with epilepsy and rhabdomyolysis - case report.

Authors:  Lucia Santoro; Dorina Pjetraj; Virtut Velmishi; Carmen Campana; Carlo Catassi; Carlo Dionisi-Vici; Arianna Maiorana
Journal:  Ital J Pediatr       Date:  2022-03-04       Impact factor: 2.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.